A new nicotine-releasing lozenge can triple smokers' chances of kicking the habit and is said to be more effective than either nicotine gum or patches, according to a study released this week.
NiQuitin CQ is produced by pharmaceutical giant GlaxoSmithKline. A clinical trial involving 1800 British and American smokers showed the lozenge to be three times as effective as a placebo in the fight to give up.
"It trebles the success rate and surpasses all form of NRT (nicotine replacement therapy) to date," said Dr Chris Steele, who runs one of Europe's biggest quit-smoking clinics. Those using the lozenges experienced a 23 percent reduction in cigarette cravings during the first week.
This website and article is not a substitute for independent professional advice. Nothing contained in this website is intended to be used as medical advice and it is not intended to be used to diagnose, treat, cure or prevent any disease, nor should it be used for therapeutic purposes or as a substitute for your own health professional's advice. All Health and any associated parties do not accept any liability for any injury, loss or damage incurred by use of or reliance on the information.
A new nicotine-releasing lozenge can triple smokers' chances of kicking the habit and is said to be more effective than either nicotine gum or patches, according to a study released this week. 
